Endocrine Abstracts

Objective: To evaluate the efficacy of canagliflozin 100 mg for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with type 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and canagliflozin 100 mg is added. Variables analyzed baseline and at 6 months...

Objetive: The change of treatment of liraglutide 1.8 mg to dapagliflozin or canaglifonzin 100 mg in patients with optimal glycemic control and stabilization weight loss, achieves progression in weight loss and improves the metabolic control of the patient with tipo 2 diabetes (DM-2). Our objective is to evaluate if there are differences in metabolic control and progression of weight loss in patients treated with canagliflozin 100 mg or dapagliflozin.Pati...

Objective: Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Since November 2020 the use of this system is subsidized in patients with type 3c diabetes (DM3c) Our objective was to describe the characteristics of these patients and their glycemic control expressed as times in range.Methods and patients: Observational longitudinal clinical study between January 2021 and December 2021 in patients with DM3c in which FGM implementat...

Objective: Cushing’s disease (CD) is the most common cause of hypercortisolism after iatrogenic origin, it represents approximately 70% of patients with endogenous Cushing’s syndrome (CS) and ectopic ACTH secretion (10%). CD is caused by a corticotropin-secreting pituitary neuroendocrine tumor (ACTH-secreting Pit-NETs), 95% of cases as a microadenoma. In ACTH-dependent CS, differential diagnosis between CD and ectopic CS must be established. 40% of CD cases, any tumo...

Objective: Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Our objective was to describe the characteristics of these patients and their glycemic control expressed as HbA1c and times in range. Methods and patientsObservational longitudinal clinical study between January 2021 and December 2021 in patients with DM1 between 14 and 18 years. Results 95 patients included. Mean age: 16.64 ± 1.25 years, with a mean DM evolution time of 6.46 ± 3....

Objective: Flash glucose monitoring (FGM) allows non-invasive glucose level assessment. Our objective was to describe the characteristics of patients in a secondary referral hospital and their glycemic control expressed as FGM targets.Methods and patientsObservational longitudinal clinical study between January 2021 and December 2021 in patients with DM1 referred to a secondary care center in Montilla (Córdoba).Results: 101 patients included. Mean a...

Objective: ACTH-secreting pituitary tumors (ACTHomas) express vasopressin (AVP) receptors. AVP receptors are also present in other types of cancer, exerting different effects on tumor growth depending on the receptor subtype. AVP type 1 receptors (V1a and V1b) are associated with stimulation of cell proliferation, AVP receptor type 2 (V2r) is associated with antiproliferative effects. Desmopressin (DAVP) is a synthetic analog of AVP that acts as a selective agonist for V2r, wh...

Objective: Adrenal venous sampling (AVS) is a reliable procedure to differentiate if in patients with primary aldosteronism (PA) aldosterone production is unilateral or bilateral and guide treatment of these patients. Our objective was to describe their characteristics and the outcomes of the AVS.Methods and patients: Observational longitudinal clinical study between July 2020 and November 2022 in patients who underwent AVS in our Hospital.<p class="...

Objective: Flash glucose monitoring (FGM) facilitates non-invasive glucose level assessment. Since November 2020 this system is subsidized in patients with type 3c diabetes (DM3c) Our objective was to describe the characteristics of these patients and their glycemic control expressed as times in range.Methods and patients: Observational longitudinal clinical study between January 2021 and January 2023 in patients with DM3c.Results:...

Objective: Preclinical studies have shown that DPP-4 inhibitors (iDPP4) have beneficial effects on functional mass of beta cells and pancreatic insulin content. The aim of this study is to evaluate the efficacy of treatment with sitagliptin in monotherapy or in combination with insulin in person with type 1 diabetes (DM-1) or type LADA diabetes (DM-LADA) of recent diagnosis.Patients and methods: Descriptive study: patients with DM-1 or DM-LADA in treatme...